DOUBLEDAY Mary
No ORCID on file
· 16 papers in corpus
· active 2000-2002
Frequent coauthors
2002
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods are…
2002
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods are…
2002
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods are…
2002
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods are…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods …
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods …
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods …
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having the following structure, as well as pharmaceutical compositions containing the same:wherein R1, R2, R3, n and p are as defined here. Methods …
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2001
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…
2000
Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having structure I, as well as pharmaceutical compositions containing the same: wherein R1, R2, R3, i(n) and i(p) are as defined here. Methods are also…